Cinacalcet
Regulatory activity · FDAAlso known as CNC, N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine, Sensipar, Cinacalcet Hydrochloride.
Recent clinical, regulatory, research and industry developments relating to this drug.
Novel Combination Therapy for Osteoporosis in Men
Parathyroid Hormone Level and Growth in Pediatric Patients With ESRD on Regular Hemodialysis
Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism
Renal Osteodystrophy: A Fresh Approach
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Novel Combination Therapy for Osteoporosis in Men
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- Clinical journal of the American Society of Nephrology : CJASN1
- Nephron. Clinical practice1
- Bos WJ2
- Bouman K2
- Braun J2
- Brink H2
- Carter D2
- Frazão JM2
- Graf H2
- Macário F2
- CROFF Policlinico di Milano1
- Sheffield Kidney Institute1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.